Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Melanoma Institute Australia
ImmunityBio, Inc.
University Hospital, Essen
Jules Bordet Institute
MultiVir, Inc.